The coronovirus vaccine developed by Oxford University and pharma giant AstraZeneca in the United Kingdom is safe and effective. British media outlet Sky News reported that the matter was confirmed in a separate review. The study was published on Tuesday in the medical journal The Lancet. Researchers say this success will have a major impact on the corona epidemic.
This is the first peer-reviewed analysis of the final phase of the Oxford Vaccine clinical trial. Scientists are exchanging information among themselves to ensure transparency about the vaccine. They expect the vaccine to be approved for use in the UK in the next few weeks.
Around 12,000 volunteers in the United Kingdom and Brazil are participating in clinical trials of the vaccine. According to the test report, it is 80.4% effective. The efficacy rate for the two dose-taking groups was 72.1%. But the group that mistakenly took half the dose first and then the whole dose reached 90 percent.
The test results have been sent to drug regulators around the world for approval.
Professor Andrew Pollard, Oxford Vaccine Group director and chief investigative officer of clinical trials, said: It has been shown that the safety and efficacy of new vaccines against coronaviruses is good.
“We are very grateful to the volunteers who participated in the clinical trial,” Pollard said. He has worked with us over the last eight months to cross this milestone.
According to the report, the cost of production of this vaccine is low and a large number of doses can be produced at low cost. Unlike the Pfizer-Bioentech vaccine, it does not need to be kept at extra cold temperatures.
Sarah Gilbert, a professor of vaccines at the University of Oxford, called the report’s release “possibly the best day of 2020”. He stated that the vaccine has been shown to be effective in many applications before clinical trials. We now have clear evidence of effectiveness after peer-review reports were published.
Sarah Gilbert said the regulatory body now had to review. We hope that soon the vaccine will start saving lives.
Clinical trials of the Oxford vaccine are still ongoing. How long the vaccine will last is also being discussed. In various countries, the Drug Regulatory Authority will decide how much vaccine dose to take. Britain has ordered tens of millions of doses of the Oxford vaccine.